A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
Otsuka Pharmaceutical and H. Lundbeck A/S have announced that the US FDA has approved the novel antipsychotic agent Rexulti (brexpiprazole). The drug is indicated for adjunctive therapy for adults with major depressive disorder (MDD) and for the treatment of adults…
To read the full story
Related Article
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
BUSINESS
- Nipro, Nichi-Iko to Consolidate Injectable Antibiotics Production by 2026
November 7, 2025
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…